clinical outcomes in early breast cancer with a high 21-gene recurrence score tailorx rct
Published 4 years ago • 260 plays • Length 1:13:21Download video MP4
Download video MP3
Similar videos
-
18:14
does 21-gene recurrence score assay testingchange decisions? dr. adher alsayed ( day 1)
-
5:34
tailorx: phase 3 trial validating a 21-gene expression assay in breast cancer
-
33:23
oncotype dx breast recurrence score assay after tailorx and rxponder: what’s next?
-
2:02
tailorx: patient-reported outcomes in breast cancer
-
3:18
5-year outcomes from planb: phase 3 trial of 21-gene recurrence score® result in breast cancer
-
3:43
early stage breast cancer: tailorx trial
-
8:44
dr richard de boer discusses the tailorx trial of oncotypedx
-
0:40
assessing the role of 21-gene assays in breast cancer
-
5:54
roxane: impact of 21-gene assay on treatment for early breast cancer
-
15:18
clinical outcomes in estrogen receptor-positive breast cancer patients with recurrence score
-
2:50
rxponder: sparing chemotherapy in node-positive early-stage breast cancer
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
4:33
tailorx: genomic test helps identify low-risk women who do not need chemotherapy
-
5:49
perspectives on the olympia study of adjuvant olaparib in early breast cancer | nadine tung
-
16:16
esso 2010: oncotype dx classifier for breast cancer
-
3:57
overview of prospective phase 3 planb trial of 21-gene recurrence score® result in breast cancer
-
5:03
what is the tailorx clinical trial?
-
12:23
recurrence score results, clinicopathologic characteristics, treatments, and outcomes -breast cancer
-
1:49
early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?